TY - JOUR AU - Xu, Yangyang AU - Wan, Bing AU - Chen, Xi AU - Zhan, Ping AU - Zhao, Yuan AU - Zhang, Tianli AU - Liu, Hongbing AU - Afzal, Muhammad Zubair AU - Dermime, Said AU - Hochwald, Steven N. AU - Hofman, Paul AU - Borghaei, Hossein AU - Lin, Dang AU - Lv, Tangfeng AU - Song, Yong AU - AME Lung Cancer Collaborative Group, written on behalf of PY - 2019 TI - The association of PD-L1 expression with the efficacy of anti- PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials JF - Translational Lung Cancer Research; Vol 8, No 4 (August 31, 2019): Translational Lung Cancer Research Y2 - 2019 KW - N2 - Background: We conducted a meta-analysis to evaluate the efficacy of anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monotherapy or immunotherapy combined with chemotherapy and further estimated the value of PD-L1 expression in predicting the response from anti-PD-1/PD-L1 treatments as monotherapy or in combination with chemotherapy. Methods: Clinical trial data were searched from electronic databases, which evaluated PD-1/PD-L1 inhibitors in non-small cell lung cancer (NSCLC) and correlated with PD-L1 expression levels. Results: Fifteen randomized-controlled trials involving 10,074 patients were identified. Comparing anti- PD-1/PD-L1 monotherapy to chemotherapy, the pooled HR for overall survival (OS) was 0.77 (95% CI: 0.69–0.85, P 2 =0%). Furthermore, immunotherapy combined with chemotherapy had better OS (HR =0.64, 95% CI: 0.48–0.84, P=0.001) than chemotherapy alone. Subgroup analyses showed that patients benefited from the combined chemo-IO treatment in the first-line setting regardless of PD-L1 expression level. Conclusions: PD-L1 expression may be a valuable predictor of the efficacy of anti-PD-1/PD-L1 monotherapy in certain NSCLC patients. However, the combination of chemotherapy plus immunotherapy significantly improved survival regardless of the PD-L1 expression level in the first-line treatment of NSCLC. UR - https://tlcr.amegroups.org/article/view/31044